|本期目录/Table of Contents|

[1]杨晓欧,高丽娟,张琳,等.社区2 型糖尿病患者调脂治疗和血脂达标情况分析[J].慢性病学杂志,2019,20(01):21-25.
　YANG Xiao-ou*,GAO Li-juan,ZHANG Lin,et al.Lipid-modifying therapy and lipid goal attainment in patients with type 2 diabetes in community[J].,2019,20(01):21-25.
点击复制

社区2 型糖尿病患者调脂治疗和血脂达标情况分析(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年01期
页码:
21-25
栏目:
论　著
出版日期:
2019-01-30

文章信息/Info

Title:
Lipid-modifying therapy and lipid goal attainment in patients with type 2 diabetes in community
作者:
杨晓欧1;  高丽娟2;  张琳1;  刘红霞1;  庄宁2
1. 北京市东城区社区卫生服务中心，北京100027 2. 北京市朝阳区劲松社区卫生服务中心，北京100021
Author(s):
YANG Xiao-ou*;  GAO Li-juan;  ZHANG Lin;  LIU Hong-xia;  ZHUANG Ning
*Community Health Service Center in Dongcheng District, Beijing 100027，China Corresponding author: ZHUANG Ning, E-mail: zhnbox@126.com
关键词:
2型糖尿病血脂异常; 社区
Keywords:
Type 2 diabetes;  Dyslipidemia;  Community
分类号:
R587.1
DOI:
-
摘要:
目的调查社区2 型糖尿病（T2DM） 患者调脂治疗和血脂达标情况。方法选取2018 年1—6 月在东 城区社区卫生服务中心随诊超过半年，年龄≥40岁的337例T2DM 患者进行调查。采用问卷调查和实验室检测收 集患者的一般资料和血脂数据，合并动脉硬化性心血管疾病（ASCVD） 者为极高危组（129 例），其他为高危组 （208 例）。根据患者服用降脂药物情况分为他汀单药治疗组、他汀+依折麦布联合治疗组、其他药物组和未服药 组。根据2016 中国成人血脂异常防治指南推荐以低密度脂蛋白胆固醇（LDL-C） 为主要目标，非高密度脂蛋白 胆固醇（non-HDL-C） 为次要目标评估患者血脂达标率。结果调脂药物使用率52.27%，他汀药物使用率 38.87%。极高危组患者LDL-C 达标率显著低于高危组患者（21.71% vs. 48.56%，P＜0.001），LDL-C 和non- HDL-C 双达标率显著低于高危组（17.05% vs. 36.06%，P＜0.001），在LDL-C 达标的患者中有24.81%non- HDL-C 不达标。他汀+依折麦布联合治疗率4.75%，他汀+依折麦布联合治疗组LDL-C 及双达标率均显著高于 其他治疗组。结论社区T2DM 患者血脂治疗率和达标率仍较低，特别是合并ASCVD 患者。联合治疗是提高 血脂达标率的有效方法，临床上应加强对2型糖尿病患者的血脂管理。
Abstract:
Objective To investigate lipid-modifying therapy and lipid goal attainment status in patients with type 2 diabetes mellitus （T2DM） in community. Methods A total of 337 patients with T2DM aged 40 years old and over were selected, who were followed up for more than half a year by Dongcheng District Community Health Service Center from January to June 2018. General information and blood lipid data were collected through questionnaires and laboratory tests, respectively. Patients with arteriosclerotic cardiovascular disease （ASCVD） were regarded as extremely-high-risk group （n= 129） , and other patients were acted as high-risk group （n=208） . According to application of lipophilic drugs, patients were divided into statin treatment group and statin united ezetimibe treatment group and other medicine treatment and non-treatment group. We evaluated the patient’s lipid goal attainment with low-density lipoprotein cholesterol （LDL-C） as the primary target and non-high-density lipoprotein cholesterol （non-HDL-C） as secondary target according to 2016 Chinese guidelines for the management of dyslipidemia. Results The lipid- lowering drug use rate was 52.27% , and the statin drug use rate was 38.87%. The rate of goal attainment for LDL-C in extremely-high-risk group was significantly lower than that in high-risk group （21.71% vs. 48.56%, P<0.001） , and the rate of dualgoal achievements of LDL-C and non-HDL-C in extremely-high-risk group were significantly lowerthan that in high- risk group （17.05% vs. 36.06% , P<0.001） . Among patients attaining goal attainment for LDL-C goal, 24.81% patietns did not attain their non-HDL-C goal. The combined treatment rate of statin + ezetimibe was 4.75%; the LDL-C goal and dual-goal achievements rates in the statin united ezetimibe treatment group were significantly higher than those in the other treatment groups. Conclusion Lipid-modifying therapy rate and lipid goal attainment rate in community T2DM patients is low, especially in patients with extremely high- risk. Combination therapy is an effective method to improve the rate of blood lipids goal attainment. Clinically, management of blood lipids should be strengthened in T2DM patients.

参考文献/References:

[1] Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines [J]. Circulation, 2014,129(25 Suppl 2):S1-S45.
[2] Grundy SM. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia [J]. J Clin Lipidol, 2013,7(6):561-565.
[3] Catapano AL, Graham I, De Backer G, et al. 2016 ESC/ EAS Guidelines for the Management of Dyslipidaemias [J]. Eur Heart J, 2016,37(39):2999-3058.
[4] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常 防治指南(2016年修订版)[J].中国循环杂志,2016(10):937-950.
[5] Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients [J]. Am J Med, 2013,126(10):925,e11-22.
[6] 杨光燃,袁申元,傅汉菁,等.北京社区2型糖尿病患者血脂异常情 况分析:北京社区糖尿病研究[J].中华全科医师杂志,2012(10):748- 752.
[7] 路晓,帅瑛,王娜,等.北京社区2型糖尿病患者心血管病风险因素 控制现状分析[J].中华糖尿病杂志,2015,19(8):474-477.
[8] Rodriguez F, Olufade T, Heithoff K, et al. Frequency of high- risk patients not receiving high- potency statin (from a large managed care database) [J]. Am J Cardiol, 2015, 115(2):190-195.
[9] 靳小龙,范昕昕,王安秀,等.非高密度脂蛋白胆固醇与新诊断2型 糖尿病患者心血管疾病风险的相关性研究[J]. 中国临床医生杂 志,2018(10):1167-1171.
[10] Zeng RX, Li XL, Zhang MZ, et al. Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes [J]. Atherosclerosis, 2014,237(2):536-543.
[11] 中华医学会糖尿病学分会. 中国2 型糖尿病防治指南(2017 年版) [J].中华糖尿病杂志,2018,22(1):4-67.
[12] Ai C, Zhang S, He Q, et al. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta- analyse [J]. Lipids Health Dis, 2018,17(1): 239.
[13] Savarese G, De Ferrari GM, Rosano GM, et al. Safety and efficacy of ezetimibe: A meta-analysis [J]. Int J Cardiol, 2015,201:247-252.
[14] Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta- analysis of randomized controlled trials [J]. Endocrine, 2018,60(2):229-239.
[15] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J]. N Engl J Med, 2015,372(25):2387-2397.
[16] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ ACC/ AACVPR/ AAPA/ ABC/ ACPM/ ADA/ AGS/ APhA/ ASPC/ NLA/ PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines [J]. J Am Coll Cardiol, 2018,11(8):S0735-1097.

备注/Memo

备注/Memo:
作者简介：杨晓欧，大学本科，主治医师，主要从事全科慢性病诊疗工作 通信作者：庄宁，E-mail: zhnbox@126.com
更新日期/Last Update: 2019-01-30